SecBot SecBot
PRESS-RELEASE ·Filed May 8, 2026

PHVS

Pharvaris N.V.
BEARISH
Impact 6/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight ▼ Bearish

The offering provides necessary capital for late-stage trials and potential NDA submission, but the dilution and insider selling are near-term negatives. Watch for the stock's reaction at open and any further insider transactions. The next major catalyst is CHAPTER-3 topline data in Q3 2026.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$30.09
T+0 close · May 8, 2026 · via day close
Latest settled
+12.56%
T+60 · $33.87
Vs SPY
+7.72%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 8 $30.09entry
  2. T+1 · 6mo ago −0.47%α −0.70% · $29.95
  3. T+5 · 6mo ago +2.03%α +0.56% · $30.70
  4. T+20 · 5mo ago +3.32%α +3.30% · $31.09
  5. T+60 · 3mo ago +12.56%α +7.72% · $33.87
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pharvaris priced a $115M underwritten offering of 3.87M shares at $29.68 per share, representing ~6% dilution. The capital raise funds late-stage HAE/AAE programs, but recent insider selling ($1.8M in 30 days) and dilution create near-term headwinds. The offering closes May 11, 2026.

Key Financial Metrics

Deal Value
$115.0M

Key Facts

  • Priced 3,874,664 ordinary shares at $29.68 per share for gross proceeds of ~$115M
  • Underwriters have a 30-day option for up to 581,199 additional shares
  • Offering expected to close on or about May 11, 2026
  • Joint book-running managers: Morgan Stanley, Leerink Partners, Cantor, Wells Fargo Securities
  • Proceeds to fund clinical development and potential commercialization of deucrictibant for HAE and AAE-C1INH
  • Recent insider selling: 4 transactions totaling $1.8M in the past 30 days

Financial Impact

~6-7% dilution based on ~64M shares outstanding implied by $1.9B market cap at $29.68; gross proceeds of $115M

dilutioncash

Risk Factors

  • Dilution of ~6-7% reduces EPS and ownership for existing shareholders
  • Insider selling ahead of offering may signal lack of confidence
  • Clinical trial risks for deucrictibant (HAE/AAE programs)
  • Regulatory approval uncertainty for NDA submission planned in H1 2026

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3290920

Track record

51 reports on PHVS

Performance horizon

15 of 17 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 16 of 18 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
  3. Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  4. Nov 12, 20264d ago 6-K Neutral 4/10 No price data
  5. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  6. Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
  7. Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  8. Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  9. Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
  10. Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
Showing 10 of 51

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 8, 2026